327 related articles for article (PubMed ID: 12671020)
1. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
3. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Waters EA; McNeel TS; Stevens WM; Freedman AN
Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Waters EA; Cronin KA; Graubard BI; Han PK; Freedman AN
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):443-6. PubMed ID: 20142242
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer risk in primary care: implications for chemoprevention.
Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ
Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765
[TBL] [Abstract][Full Text] [Related]
8. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
[No Abstract] [Full Text] [Related]
9. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
Rockhill B; Spiegelman D; Byrne C; Hunter DJ; Colditz GA
J Natl Cancer Inst; 2001 Mar; 93(5):358-66. PubMed ID: 11238697
[TBL] [Abstract][Full Text] [Related]
10. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL
J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758
[TBL] [Abstract][Full Text] [Related]
11. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Levine M; Moutquin JM; Walton R; Feightner J;
CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.
Green LE; Dinh TA; Hinds DA; Walser BL; Allman R
Appl Health Econ Health Policy; 2014 Apr; 12(2):203-17. PubMed ID: 24595521
[TBL] [Abstract][Full Text] [Related]
15. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
[TBL] [Abstract][Full Text] [Related]
16. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
17. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of breast cancer: recommendations and rationale.
U.S. Preventive Services Task Force
Ann Intern Med; 2002 Jul; 137(1):56-8. PubMed ID: 12093249
[No Abstract] [Full Text] [Related]
19. Role of hormones in cancer prevention.
Vogel VG
Am Soc Clin Oncol Educ Book; 2014; ():34-40. PubMed ID: 24857058
[TBL] [Abstract][Full Text] [Related]
20. Projecting individualized absolute invasive breast cancer risk in African American women.
Gail MH; Costantino JP; Pee D; Bondy M; Newman L; Selvan M; Anderson GL; Malone KE; Marchbanks PA; McCaskill-Stevens W; Norman SA; Simon MS; Spirtas R; Ursin G; Bernstein L
J Natl Cancer Inst; 2007 Dec; 99(23):1782-92. PubMed ID: 18042936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
